This on-demand presentation covers manufactured respirable 5AZA powder using a modified spray drying process. Pharmacokinetics of inhaled dry powder and aqueous formulations of 5AZA is compared to an injected formulation. Efficacy studies and effect of therapy on the epigenome were conducted in an orthotopic rat lung cancer model for inhaled formulations. These findings could lead to widespread use of this drug as the first inhaled dry powder therapeutic for treating local and metastatic lung cancer, for adjuvant therapy, and in combination with immunotherapy to improve patient survival.  To learn more, watch our presentation.
Content Type: Presentation (on-demand)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center